Citigroup
VRDN icon

Citigroup’s Viridian Therapeutics VRDN Stock Holding History

Citigroup’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30,000
Closed -$763K – 5738
2023
Q1 		$763K Buy
+30,000
New +$962K ﹤0.01% 2775

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Citigroup's VRDN Position: Q2 2026 in Review

Citigroup increased its Viridian Therapeutics (VRDN) stake by 499% in Q2 2026, buying an estimated $1.88M and bringing the position to 140,415 shares worth $2.58M. The position accounts for ﹤0.01% of the portfolio, ranked #2739.

Citigroup first reported a position in VRDN in Q4 2014 and has held it in 32 quarters since. The position peaked at $6.09M in Q1 2024. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Citigroup held 140,415 shares of Viridian Therapeutics worth $2.58M as of Q2 2026.
  • Citigroup bought 116,957 Viridian Therapeutics shares in Q2 2026, an estimated $1.88M.
  • Viridian Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2739 holding.
  • Citigroup first reported a position in Viridian Therapeutics in Q4 2014 and has held it in 32 quarters since.
  • Citigroup's Viridian Therapeutics position peaked at $6.09M in Q1 2024.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.